Outcomes:
Our primary outcomes were the percent of patients with tumor thrombus
who received anticoagulation in combination with cancer-directed
therapies and the rate of bland tumor formation in patients treated with
or without anticoagulation.
Our secondary outcomes were all-cause mortalities; and the rate of
clinically relevant, non-major or minor bleeding, and/or major bleeding.